Point72 (DIFC)’s iTeos Therapeutics ITOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-8,794
Closed -$67.5K 1867
2024
Q4
$67.5K Buy
8,794
+5,795
+193% +$49.8K ﹤0.01% 1077
2024
Q3
$30.6K Buy
+2,999
New +$45.8K ﹤0.01% 1161
2024
Q2
Sell
-1,233
Closed -$16.8K 1679
2024
Q1
$16.8K Buy
+1,233
New +$13.4K ﹤0.01% 1313

Other funds holding ITOS

Point72 (DIFC)'s ITOS Position: Q1 2025 in Review

Point72 (DIFC) sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 8,794 shares — an estimated $67.5K sold.

Point72 (DIFC) first reported a position in ITOS in Q1 2024 and held it in 3 quarters. The position peaked at $67.5K in Q4 2024. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • Point72 (DIFC) reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 8,794 iTeos Therapeutics shares in Q1 2025, an estimated $67.5K.
  • Point72 (DIFC) first reported a position in iTeos Therapeutics in Q1 2024 and held it in 3 quarters.
  • Point72 (DIFC)'s iTeos Therapeutics position peaked at $67.5K in Q4 2024.
  • 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.